176
Participants
Start Date
February 28, 2011
Primary Completion Date
March 31, 2012
Study Completion Date
October 31, 2012
ombrabulin (AVE8062)
"Pharmaceutical form:solution~Route of administration: intravenous"
placebo
"Pharmaceutical form:solution~Route of administration: intravenous"
Investigational Site Number 804003, Kyiv
Investigational Site Number 036002, Bendigo
Investigational Site Number 036001, Southport
Investigational Site Number 191002, Zagreb
Investigational Site Number 191003, Zagreb
Investigational Site Number 688003, Belgrade
Investigational Site Number 380002, Genova
Investigational Site Number 380001, Monza
Investigational Site Number 380003, Milan
Investigational Site Number 250002, Dijon
Investigational Site Number 688001, Kamenitz
Investigational Site Number 276002, Großhansdorf
Investigational Site Number 250005, Bordeaux
Investigational Site Number 276003, Immenhausen
Investigational Site Number 840001, Muscle Shoals
Investigational Site Number 804002, Sumy
Investigational Site Number 250001, Saint-Herblain
Investigational Site Number 840005, Lansing
Investigational Site Number 804001, Dnipropetrovsk
Investigational Site Number 250003, Lyon
Investigational Site Number 840003, Hot Springs
Investigational Site Number 276001, Gauting
Investigational Site Number 840002, Anaheim
Investigational Site Number 840009, Modesto
Investigational Site Number 643002, Moscow
Investigational Site Number 643004, Saint Petersburg
Investigational Site Number 642004, Craiova
Investigational Site Number 642003, Cluj-Napoca
Investigational Site Number 642001, Iași
Investigational Site Number 152004, Valparaíso
Investigational Site Number 152002, Santiago
Investigational Site Number 152003, Santiago
Investigational Site Number 152005, Santiago
Investigational Site Number 191001, Zagreb
Investigational Site Number 250004, Nice
Investigational Site Number 616003, Lublin
Investigational Site Number 616001, Poznan
Investigational Site Number 616004, Warsaw
Investigational Site Number 616005, Warsaw
Investigational Site Number 642002, Bucharest
Investigational Site Number 410003, Seoul
Investigational Site Number 410002, Seoul
Investigational Site Number 410001, Seoul
Lead Sponsor
Sanofi
INDUSTRY